Regarding “Percutaneous angioplasty and stenting of the superficial femoral artery”  by Takagi, Hisato et al.
I would like to thank Dr Lee for his questions. I hope that this
will stimulate more physicians to adopt and test these methods.
Ningfei Liu, MD, PhD
Department of Plastic and Reconstructive Surgery
Shanghai Second Medical University
Shanghai 9th People’s Hospital
Shanghai, China
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Regarding: “The study of endovascular repair of
small (<5.5-cm) aneurysms”
A multi-institutional national investigational study is being
proposed to determine whether endovascular repair (EVAR) sur-
gery is worthwhile for treating patients with small abdominal aortic
aneurysms. It is my feeling that such data are already available and
that participation in such a study would be detrimental to patient
safety. The rates of complications associated with this type of
surgery are summarized in Table I. These impressive complications
must be compared with the annual 0% to 1.0% risk of rupture and
death for small, untreated aneurysms.1,6
The estimated cost to follow up patients with EVAR (com-
puted tomographic scans) together with the cost of repairs and
reoperations exceeded $50 million in 2001. These morbidity and
mortality data fail to reflect the disrupted quality of life sustained by
patients who undergo this type of aneurysm repair. The data also
fail to indicate that the vast majority of patients with small aneu-
rysms can undergo intervention when their aneurysm reaches the
5.5-cm threshold.6
As such, I believe that participation in this study is neither
morally nor scientifically justified.
Thank you for your consideration.
Arthur E. Palamara, MD, FACS
Department of Surgery
University of Miami
School of Medicine
Hollywood, Fla
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Reply
The letter from Dr Arthur Palamara addresses the clinical
equipoise of endovascular repair vs ultrasound surveillance for
small aortic aneurysms. Dr Palamara suggests that the existing data
are compelling, with a complication rate and an economic burden
of endovascular aneurysm repair that exceed observation alone.
But where is the evidence to support this contention? Today,
many practitioners continue to repair smaller aneurysms; in fact,
the mean size of aneurysms repaired in the endovascular clinical
trials remains just below 5.5 cm. Importantly, there exist no
objective data comparing endovascular repair with surveillance of
smaller abdominal aortic aneurysms. In an age of evidence-based
medicine, treatment decisions can no longer be made on the basis
of anecdotal experience. Rather, well-designed, multicenter, ade-
quately powered clinical trials should be performed and the results
analyzed. The support of such studies is incumbent upon us all; to
oppose them deprives the vascular surgical community of answers
to important, clinically relevant questions.
Kenneth Ouriel, MD
The Cleveland Clinic Foundation
Cleveland, Ohio
doi:10.1016/j.jvs.2005.06.008
Regarding “Percutaneous angioplasty and stenting of
the superficial femoral artery”
We read with interest the article by Surowiec et al (J Vasc Surg
2005;41:269-78) regarding percutaneous angioplasty and stent-
ing of the superficial femoral artery, and we greatly appreciate their
excellent results. In their study, stents were used, at the discretion
of the operator, for flow-limited dissections, intimal flaps, or poor
technical results, and primary stenting was used for Trans Atlantic
Inter-Society Consensus C and D lesions in general. Furthermore,
stents were used preferentially to re-establish a flow lumen for
complete occlusions. They used stents in 139 (37%) of 380 lesions
as a result and have stated that the performance of angioplasty only
was found to be protective from loss of patency (hazard ratio, 0.43;
95% confidence interval [CI], 0.22-0.84). The use of stents as an
adjunct to balloon dilatation may improve the patency of percuta-
neous revascularization for femoropopliteal arterial disease, as well
as for coronary or iliac artery disease. Muradin et al1 have per-
formed a meta-analysis of the long-term results of percutaneous
transluminal angioplasty (PTA) and stent implantation (STI) in the
Table I. Complications of endovascular repair
Variable
Small and large
aneurysms
Small (5.5-cm)
aneurysms
Graft migration 3.6%1 6.0%2
Endoleaks (all) 30.0%1
Type Ia and b 16.6%3
Type III 14.4%3
Graft failure 3.0%4
Graft limb occlusion 2.8%5
Conversion
Early 5%5 1.4%2 (2 y)
Late 8.2%2 6.6%3 (4 y)
Secondary procedures 35%5 40.0%2
Death
Perioperative 1.7%4 1.6%2
30 d 1.6%2
1 y 8.2%2 (all causes)
2 y 6.1%2 1.5%2
4 y 3.0%3
Rupture (4 y) 10.0%4 1.7%3
Aneurysm expansion 15.2%3
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treatment of femoropopliteal arterial disease, including 1 random-
ized controlled trial (RCT)2 and 18 nonrandomized studies. Al-
though publication bias could not be ruled out, PTA and STI for
claudication and stenosis yielded similar long-term patency, and
the results of STI seemed more favorable for more severe femoro-
popliteal disease. To our knowledge, however, no meta-analysis of
only RCTs regarding the results of STI vs PTA for femoropopliteal
lesions has been reported. To assess whether STI improves the
patency of femoropopliteal lesions compared with PTA, we con-
ducted a meta-analysis of currently available RCTs.
We searched MEDLINE through March 2005 and identified
4 RCTs that compared the patency of STI vs PTA of femoropop-
liteal lesions.2-5 Characteristics of the trials and a meta-analysis of
patency are shown in the Table. A total of 290 lesions were
randomly assigned to PTA (n  144) and STI (n  146). The
percentage of lesions with an occlusion varied from 18% to 100%
(40% of the weighted mean), and that of poor runoff varied from
0% to 37.5% (18% of the weighted mean) across the 4 RCTs. A
random-effects model (DerSimonian-Laird method) indicated no
significant difference in primary 1-year patency between PTA
(71.7%) and STI (73.7%): the odds ratio (OR) for occlusion after
the intervention (1, favors STI; 1, favors PTA) was 0.94 (95%
CI, 0.54-1.67). There was no significant heterogeneity (P .36),
and a funnel plot confirmed its symmetry with the Begg method
(P  .50), which revealed no significant publication bias. In
sensitivity analyses, removing any of the 4 RCTs separately did not
show a large effect on the results. Secondary 1-year and primary
and secondary 2-year patencies have been described in only 2
trials.4,5 There were no significant differences in primary 2-year
patency (67.8% vs 67.1%; OR, 1.06; 95% CI, 0.59-1.90) or sec-
ondary 2-year patency (84.8% vs 76.3%; OR, 1.83; 95% CI, 0.90-
3.73) between PTA and STI.
Table. Characteristics of trials and meta-analysis of patency
Variable Vroegindeweij et al2 Zdanowski et al3
Year 1997 1999
Stent Palmaz Strecker
No. of patients (PTA/STI) 51 (27/24) 32 (17/15)
Age (y) 41-82 41-86
PTA/STI 64† (41-82)/65† (46-78) 71§ (41-86)/72§ (62-80)
Sex (male:female) 36:15 14:18
PTA/STI 19:8/17:7 4:13/10:5
Fontaine stage II:III:IV 51:0:0 5:6:21
PTA/STI 27:0:0/24:0:0 3:3:11/2:3:10
Ankle-brachial index NA 0.45§ (0.13-0.79)
PTA/STI NA 0.42§ (0.19-0.65)/
0.48§ (0.13-0.79)
Occlusion (PTA/STI) 9 (18%) (5/4) 32 (100%) (17/15)
Runoff
Poor¶ (PTA/STI) 5 (10%) (3/2) 12 (37.5%) (5/7)
Good# (PTA/STI) 46 (90%) (24/22) 20 (62.5%) (12/8)
Follow-up Doppler ultrasonography Clinical
Primary patency (%)
1 y
PTA 74 47
STI 62 57
Odds ratio†† (95% CI) 1.74 (0.53-4.74) 0.44 (0.09-2.11)
2 y
PTA NA NA
STI NA NA
Odds ratio†† (95% CI) — —
Secondary patency (%)
1 y
PTA NA NA
STI NA NA
Odds ratio†† (95% CI) — —
2 y
PTA NA NA
STI NA NA
Odds ratio†† (95% CI) — —
PTA, Percutaneous transluminal angioplasty; STI, stent implantation; NA, not available; CI, confidence interval.
*Number of limbs.
†Mean.
‡Range excluding Grimm’s trial.
§Median.
Total excluding Grimm’s trial.
¶0-1 patent calf vessel.
#2-3 patent calf vessels.
**Weighted mean.
††Odds ratio for occlusion following the intervention (1, favors stent implantation; 1, favors percutaneous transluminal angioplasty).
‡‡Mean based on a random-effects model (DerSimonian-Laird method).
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The present meta-analysis of currently available RCTs demon-
strated that STI of femoropopliteal lesions does not improve
primary 1-year patency compared with PTA.
Hisato Takagi, MD, PhD
Seishiro Sekino, MD
Takayoshi Kato, MD
Yukihiro Matsuno, MD, PhD
Takuya Umemoto, MD, PhD
Department of Cardiovascular Surgery
Shizuoka Medical Center
Shizuoka, Japan
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Table. Continued
Cejna et al4 Grimm et al5 Total
2001 2001 —
Palmaz Palmaz Strecker:Palmaz  32:258
154 (77/77)* 53 (23/30) 290 (144/146)
67† (39-87) NA 39-87‡
65.5† (39.2-83)/68.6† (39.2-87) 68.1  8.4/70.5  9.8 39-86‡/39-87‡
95:59 32:21 177 (61%):113 (39%)
46:31/49:28 10:13/22:8 79:65/98:48
108:18:28 NA 164 (69%):24 (10%):49 (21%)
58:7:12/50:11:16 2.8  0.4/2.6  0.5 88:10:23/76:14:26
NA NA —
NA 0.62  0.3/0.47  0.36 —
60 (39%) (25/35) 16 (30%) (3/13) 117 (40%) (50/67)
36 (23%) (15/21) 0 (0/0) 53 (18%) (23/30)
118 (77%) (62/56) 53 (100%) (23/30) 237 (82%) (121/116)
Clinical/hemodynamic Doppler ultrasonography —
72 84.2 71.7**
78 75 73.7**
0.73 (0.35-1.51) 1.78 (0.44-7.15) 0.94 (0.54-1.67)‡‡
65 77.7 67.8**
65 72.4 67.1**
1.00 (0.52-1.94) 1.29 (0.37-4.55) 1.06 (0.59-1.90)‡‡
90 100 92.3**
86 90 87.1**
1.47 (0.55-3.92) — —
83 90.9 84.8**
71 90 76.3**
1.99 (0.92-4.32) 1.11 (0.17-7.10) 1.83 (0.90-3.73)‡‡
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